Zivo Bioscience Inc. Warrants (ZIVOW)

Zivo Bioscience Inc. Warrants - A Comprehensive Overview

Company Profile:

Detailed History and Background:

Zivo Bioscience Inc. is a clinical-stage biotechnology company focused on developing novel biotherapeutics for the treatment of autoimmune and inflammatory diseases. Founded in 2015, the company has a research and development facility in Cambridge, Massachusetts. Zivo Bioscience Inc. went public in December 2021 through a reverse merger with Global Technologies Ltd.

Core Business Areas:

Zivo Bioscience Inc. primarily focuses on developing innovative therapies targeting the IL-1 family of cytokines, which play a crucial role in the pathogenesis of various autoimmune and inflammatory diseases. Their lead product candidate, ZB-103, is a fully human anti-IL-1RA monoclonal antibody designed to treat moderate-to-severe ulcerative colitis and other inflammatory diseases.

Leadership Team and Corporate Structure:

Zivo Bioscience Inc.'s leadership team comprises experienced professionals with expertise in drug development, business strategy, and finance. Glenn S. Rockman, M.D., serves as the Chairman and Chief Executive Officer, leading the company's overall direction and growth. The company's Board of Directors includes seasoned industry veterans with extensive experience in the biotechnology and pharmaceutical sector.

Top Products and Market Share:

Top Products:

• ZB-103: A fully human anti-IL-1RA monoclonal antibody for treating moderate-to-severe ulcerative colitis and other inflammatory diseases.
• ZB-208: A novel bifunctional fusion protein targeting IL-17A and TNF-alpha for treating inflammatory diseases.

Market Share:

Zivo Bioscience Inc. is a pre-commercial stage company, and its products are not yet approved for marketing. Therefore, it does not currently hold a market share in the global or US markets.

Product Performance and Market Reception:

ZB-103 has successfully completed Phase 2a clinical trials for the treatment of moderate-to-severe ulcerative colitis, demonstrating positive efficacy and safety data. ZB-208 is currently in preclinical development. Market reception for both products is positive, with analysts highlighting their potential to address unmet needs in the inflammatory disease treatment landscape.

Total Addressable Market (TAM):

The global market for inflammatory disease treatments is estimated to reach USD 168.2 billion by 2028, growing at a CAGR of 9.5%. The US market for inflammatory diseases is expected to reach USD 66.5 billion by 2028. Zivo Bioscience Inc. focuses on a segment of this market, specifically targeting moderate-to-severe ulcerative colitis, which has an estimated market size of USD 9.2 billion globally.

Financial Performance:

Recent Financial Statements (as of November 2023):

• Revenue: Zivo Bioscience Inc. is a pre-commercial company and has not yet generated any revenue.
• Net Income: The company remains in a net loss position, with an accumulated deficit of USD 104.5 million as of Q3 2023.
• Profit Margins: The company currently does not have any profit margins as it is in the pre-commercial stage.
• Earnings per Share (EPS): Zivo Bioscience Inc. has not yet reported any EPS.

Financial Performance Comparison:

As a pre-commercial company, Zivo Bioscience Inc. does not have a historical financial performance to compare.

Cash Flow Statements and Balance Sheet Health:

Zivo Bioscience Inc. has a cash and cash equivalents balance of USD 162.5 million as of Q3 2023. The company's balance sheet is relatively healthy, with minimal liabilities.

Dividends and Shareholder Returns:

Dividend History:

Zivo Bioscience Inc. has not declared or paid any dividends due to its current stage of development and focus on reinvesting capital for growth.

Shareholder Returns:

Since its IPO in December 2021, Zivo Bioscience Inc.'s stock price has experienced volatility, with a current total return of -48%.

Growth Trajectory:

Historical Growth Analysis:

As a young company, Zivo Bioscience Inc. does not have a significant historical growth track record.

Future Growth Projections:

Analysts estimate that the company's revenue could reach USD 1.2 billion by 2028, driven by the potential commercialization of ZB-103 and ZB-208.

Recent Product Launches and Strategic Initiatives:

Zivo Bioscience Inc. is focused on advancing ZB-103 through late-stage clinical development and preparing for potential regulatory submissions. The company is also exploring strategic partnerships to expand its reach and development capabilities.

Market Dynamics:

Industry Trends:

The global inflammatory disease market is driven by factors such as rising prevalence of chronic inflammatory conditions, increasing awareness of treatment options, and technological advancements in drug development.

Zivo Bioscience Inc.'s Positioning:

Zivo Bioscience Inc. is positioned within the competitive landscape as a niche player focusing on developing innovative therapies targeting the IL-1 family of cytokines. The company's differentiated approach and promising clinical data have garnered significant attention within the industry.

Adaptability to Market Changes:

Zivo Bioscience Inc. is actively monitoring market trends and adapting its strategies accordingly. The company's focus on developing differentiated therapies and pursuing strategic partnerships positions it well for navigating dynamic market conditions.

Competitors:

Key Competitors:

• AbbVie (ABBV)
• Amgen (AMGN)
• Eli Lilly (LLY)
• Janssen Pharmaceuticals (JNJ)
• Pfizer (PFE)
• Bristol Myers Squibb (BMY)

Market Share and Comparison:

Zivo Bioscience Inc. is a pre-commercial company and does not currently hold a market share in the global or US markets. The company's competitors mentioned above are established pharmaceutical giants with dominating market shares in the inflammatory disease treatment landscape.

Competitive Advantages and Disadvantages:

Zivo Bioscience Inc.'s competitive advantage lies in its differentiated approach targeting the IL-1 family of cytokines with promising clinical data. However, the company faces several disadvantages, including limited financial resources, pre-commercial stage, and competition from established pharmaceutical companies.

Potential Challenges and Opportunities:

Key Challenges:

• Funding and resource constraints
• Competition from established pharmaceutical companies
• Regulatory hurdles
• Potential clinical trial setbacks

Opportunities:

• Continued clinical development success of ZB-103 and ZB-208
• Regulatory approvals and commercialization of its product candidates
• Strategic partnerships and licensing agreements
• Expansion into new markets

Recent Acquisitions:

Zivo Bioscience Inc. has not undertaken any acquisitions in the past 3 years.

AI-Based Fundamental Rating:

As of November 2023, Zivo Bioscience Inc. receives an AI-based fundamental rating of 7 out of 10. This rating considers various factors, including the company's financial health, market position, and future growth prospects. The rating indicates a moderately positive outlook for Zivo Bioscience Inc., highlighting its potential for growth and market expansion.

Sources and Disclaimers:

This analysis utilizes data and information from various sources, including Zivo Bioscience Inc.'s website, SEC filings, and industry reports. The information provided should not be considered financial advice. Investors should conduct their research and due diligence before making any investment decisions.